The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Brigham researchers reverse chemotherapy-related fertility loss using cell-based therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A new study by investigators from Brigham and Women’s Hospital in a preclinical model demonstrates the potential for restoring fertility when the ovaries have stopped working. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting. 
ClinicalReal-world Evidence

Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study shows
FDA says raw images enrich the data when used with clinician assessments

A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
By Matthew Bin Han Ong
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account